Skip to content
The Kids Research Institute Australia logo
Donate

No results yet

Search

Participating Sites and Investigators

The CIRCA DIEM Study is a multicentre study, involving several different hospital sites across Australia. Here, you can find out more about which hospitals recruit babies into the CIRCA DIEM Study.

Research

Coalition to Advance Vaccines Against Group A Streptococcus (CANVAS): A Trans-Tasman Initiative Against Rheumatic Fever

CANVAS is a commitment by the Governments of Australia and New Zealand to advance the development of a vaccine against GAS infection, which can cause rheumatic fever.

Research

Colostrum, the missing link for healthy growth

Valerie Verhasselt MD, PhD Head, Immunology and Breastfeeding 0402997617 Valerie.verhasselt@thekids.org.au Head, Immunology and Breastfeeding @

Research

Community immunity: Developing a sensitive and specific SARS-CoV-2 antibody test

Peter Richmond MBBS MRCP(UK) FRACP Head, Vaccine Trials Group Head, Vaccine Trials Group Professor Peter Richmond is Head of the Vaccine Trials Group

Research

Complex Experiences of Gender Affirmation

This project explores the mental health and support needs of Australians with complex experiences of gender-affirmation.

Research

A CHAF1B-Dependent Molecular Switch in Hematopoiesis and Leukemia Pathogenesis

Here we report that CHAF1B is required for normal hematopoiesis while its overexpression promotes leukemia

Research

An economic case for a vaccine to prevent group A streptococcus skin infections

A vaccine that prevents GAS cellulitis and other skin infections, in addition to throat infections, would maximise its value and commercial viability

Research

Global supermarkets' corporate social responsibility commitments to public health: A content analysis

Investigate the world's largest and most powerful supermarkets' publically available CSR commitments to determine their potential impact on public health

Research

Primary prevention of rheumatic fever in the 21st century: evaluation of a national programme

Population-based primary prevention of ARF through sore throat management may be effective in well-resourced settings like New Zealand